Incretin therapies have received much attention because of their tissue-protective effects, which extend beyond those associated with glycemic control. Cancer is a primary cause of death in patients who have diabetes mellitus. We previously reported antiprostate cancer effects of the glucagonlike peptide-1 (GLP-1) receptor (GLP-1R) agonist exendin-4 (Ex-4). Breast cancer is one of the most common cancers in female patients who have type 2 diabetes mellitus and obesity. Thus, we examined whether GLP-1 action could attenuate breast cancer. GLP-1R was expressed in human breast cancer tissue and MCF-7, MDA-MB-231, and KPL-1 cell lines. We found that 0.1 to 10 nM Ex-4 significantly decreased the number of breast cancer cells in a dose-dependent manner. Although Ex-4 did not induce apoptosis, it attenuated breast cancer cell proliferation significantly and dose-dependently. However, the dipeptidyl peptidase-4 inhibitor linagliptin did not affect breast cancer cell proliferation. When MCF-7 cells were transplanted into athymic mice, Ex-4 decreased MCF-7 tumor size in vivo. Ki67 immunohistochemistry revealed that breast cancer cell proliferation was significantly reduced in tumors extracted from Ex-4-treated mice. In MCF-7 cells, Ex-4 significantly inhibited nuclear factor κB (NF-κB ) nuclear translocation and target gene expression. Furthermore, Ex-4 decreased both Akt and IκB phosphorylation. These results suggest that GLP-1 could attenuate breast cancer cell proliferation via activation of GLP-1R and subsequent inhibition of NF-κB activation.
Pubmed ID: 29045658 RIS Download
Mesh terms: Adult | Animals | Breast Neoplasms | Cell Line, Tumor | Cell Proliferation | Female | Gene Expression Regulation, Neoplastic | Glucagon-Like Peptide-1 Receptor | Humans | Incretins | MCF-7 Cells | Mice, Nude | Middle Aged | NF-kappa B | Peptides | Venoms | Xenograft Model Antitumor Assays
Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.
This polyclonal antibody targets GAPDH (V-18)View all literature mentions
This monoclonal antibody targets FLAGView all literature mentions
This monoclonal antibody targets IkappaB-alphaView all literature mentions
This polyclonal antibody targets Ki67View all literature mentions
This polyclonal antibody targets AktView all literature mentions
This monoclonal antibody targets Phospho-Akt (Thr308) (C31E5E) Rabbit mAbView all literature mentions